Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Worst Sandstorm In Decade Strikes Respiratory Fear In China's Capital

New Drugs, Expanded Access, Early Studies Key

Executive Summary

Smoking, pollution, pandemics and now sandstorms - China faces a rising respiratory disease burden as companies aim to tackle it with new products.

You may also be interested in...



Alibaba's Unprecedented $2.8bn Fine Could Signal Start Of Antitrust Wave In China

China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. Past cases show the pharma sector is not immune and while it remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions. 

China COVID-19 Vaccines Efficacy Inadequate? Hot Debate, Variant Worries Swirl

China's regulators and spin doctors rush to remedy a comment from the nation’s top infectious disease official about the “not high” protection rate for its COVID-19 vaccines, amid debate over speedy development using mature technologies and doubts over protection in seniors. A slow roll-out is already presenting challenges to meeting an official 40% target.

Pharma Not Immune From Coming Antitrust Wave In China

China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. While the pharma sector remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel